Development of MK-4830 (anti-ILT4 mAb) to Target Immunosuppressive Myeloid Cells for the Treatment of Human Malignancies

Time: 2:00 pm
day: Discovery & Pre-Clinical Development – Day 2 pm


  • MK-4830 is a fully human monoclonal antibody that targets ILT4 and blocks its binding to cognate ligands
  • ILT4-blockade by MK-4830 alters the phenotype and function of myeloid-derived suppressor cells
  • MK-4830 treatment induced tumor growth inhibition of a human cancer cell line in a humanized mouse model system
  • MK-4830 and pembrolizumab combination therapy provides clinical benefit to patients enrolled in MK- 4830-001 Phase 1b study